No black box warning on record for Stribild

As of the latest FDA labeling reviewed, Stribild (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Stribild medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Avoid administering STRIBILD with concurrent or recent use of nephrotoxic drugs. ( 5.2 ) Lactic acidosis/severe hepatomegaly with steatosis: Discontinue treatment in patients who develop symptoms or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity.

No black box warning on record for Stribild

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Avoid administering STRIBILD with concurrent or recent use of nephrotoxic drugs. ( 5.2 ) Lactic acidosis/severe hepatomegaly with steatosis: Discontinue treatment in patients who develop symptoms or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity.

Stribild Black Box Warning

No black box warning on record for Stribild

Other warnings & precautions

Stribild Black Box Warning

No black box warning on record for Stribild

Other warnings & precautions